Showing 1241-1250 of 4801 results for "".
Mechanism of Action Matters: A Review of New and Emerging Biologics
https://practicaldermatology.com/issues/supplements/mechanism-of-action-matters-a-review-of-new-and-emerging-biologics/23178/Protect or Defend: Sorting Through Oral Supplement Claims
https://practicaldermatology.com/topics/skin-cancer-photoprotection/protect-or-defend-sorting-through-oral-supplement-claims/20470/A recent FDA action calls attention to unfounded claims, but it may create some confusion.Evolving Perspectives: The Impact of COVID-19 on the Dermatology Market and Consolidation Activity
https://practicaldermatology.com/topics/practice-management/evolving-perspectives-the-impact-of-covid-19-on-the-dermatology-market-and-consolidation-activity/23347/Experts weigh in on the effect of COVID-19 on Mergers & Acquisitions trends in dermatology.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyPhysician Spotlight
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight/20685/Practicing picture-perfect dermatology.Currents
https://practicaldermatology.com/topics/practice-management/currents-7/23346/Conversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiWhy Consider Lasers?
https://practicaldermatology.com/topics/practice-management/why-consider-lasers/18863/Should younger dermatologists add devices to their practice? Laser expert Eric Bernstein, MD talks about the decision to embrace technology and explains how it can mold the future of those who have a passion for lasers and other energy-based devices. Watch other PD Asks videos with Eric BernsteinI knew I wanted to become a dermatologist when...
https://practicaldermatology.com/topics/practice-management/i-knew-i-wanted-to-become-a-dermatologist-when---opefutim/18682/PD Asks: When Yolanda Lenzy, MD was about 13 years old she visited the office of Dr. Lynn McKinley Grant in Washington, DC. It was her first experience with an African American physician, and Dr. Lenzy describes how Dr. McKinley Grant inspired and supported her aspirations. Watch other responses toDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)